{
    "organizations": [],
    "uuid": "8bc2f9cf61ffc914acb6975139fe1b7399bd0ffc",
    "author": "",
    "url": "https://www.reuters.com/article/brief-amicus-therapeutics-announces-appr/brief-amicus-therapeutics-announces-approval-of-galafold-for-fabry-disease-in-japan-idUSFWN1R4145",
    "ord_in_thread": 0,
    "title": "BRIEF-‍Amicus Therapeutics Announces Approval Of Galafold For Fabry Disease In Japan​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 23, 2018 / 1:40 AM / Updated 11 minutes ago BRIEF-‍Amicus Therapeutics Announces Approval Of Galafold For Fabry Disease In Japan​ Reuters Staff March 22 (Reuters) - Amicus Therapeutics Inc: * ‍AMICUS THERAPEUTICS ANNOUNCES APPROVAL OF GALAFOLD® (MIGALASTAT) FOR FABRY DISEASE IN JAPAN​ * ‍ANTICIPATES LAUNCHING GALAFOLD IN JAPAN IN COMING MONTHS​ * ‍WILL NOW PROCEED WITH PRICING AND REIMBURSEMENT PROCESSES​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-23T04:39:00.000+03:00",
    "crawled": "2018-03-23T04:59:42.039+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "announces",
        "approval",
        "galafold",
        "fabry",
        "disease",
        "reuters",
        "staff",
        "march",
        "reuters",
        "amicus",
        "therapeutic",
        "inc",
        "therapeutic",
        "announces",
        "approval",
        "migalastat",
        "fabry",
        "disease",
        "launching",
        "galafold",
        "japan",
        "coming",
        "proceed",
        "pricing",
        "reimbursement",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}